Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
Head-to-head evidence comparison — which supplement is right for you?
Empagliflozin vs Orlistat: they're closely matched on evidence (4.5 vs 6/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 2-minute quiz for a pick tailored to your goals.
Empagliflozin and Orlistat are closely matched across evidence, studies, and safety.
Verdict
Helped
7 of 7 studies with measurable effects showed benefit.
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (1)
Outcomes where both Empagliflozin and Orlistat have evidence — compare verdict strength side-by-side.
A source-matched dose range is not available for this product and use.
If this treatment was prescribed for you, follow your prescriber’s directions. Do not change prescribed treatment because this page has no matched dose range.
Morning
Oral tablet (empagliflozin)
A source-matched dose range is not available for this product and use.
If this treatment was prescribed for you, follow your prescriber’s directions. Do not change prescribed treatment because this page has no matched dose range.
With meals
Xenical 120 mg capsule (prescription formulation).
and 2 more not shown
Weeks
Months to years
Months to years
Weeks to months
4–12 weeks to onset; maximal by 6–12 months
Year 2 of continuous use
Years
3–12 months
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · RCT · n=7020
EMPA-REG OUTCOME randomized trial in high-CV-risk type-2 diabetics
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation (2018) · RCT
Randomized evidence of empagliflozin benefit in established cardiovascular disease
Empagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2023) · RCT
EMPA-KIDNEY randomized trial in a broad chronic-kidney-disease population
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.
Diabetes Care (2004) · RCT · n=3305
4-year double-blind trial randomising 3,305 obese patients (BMI ≥30) to lifestyle changes plus orlistat 120 mg or placebo three times daily
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
Lancet (1998) · RCT · n=688
743 obese patients (BMI 28–47) entered a 4-week placebo lead-in at 15 European centres; 688 were randomised double-blind to orlistat 120 mg three times a day or placebo for 1 year on a 600 kcal/day-deficit diet, then reassigned for a second 52-week weight-maintenance period
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
JAMA (1999) · RCT · n=892
2-year randomised, double-blind, placebo-controlled trial at 18 US research centres; 1,187 obese adults (BMI 30–43) entered and 892 were randomised, with 223 placebo- and 657 orlistat-treated subjects in the intent-to-treat analysis
Both Empagliflozin and Orlistat are closely matched — the best choice depends on your specific health goals.
For manage weight, Orlistat has a higher relevance score (72 vs 45).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.